These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 39317345

  • 1. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.
    Wang J, Zhang Z, Zhu L, Zhang Q, Zhang S, Pan Y, Liu J, Cao F, Fan T, Xiong Y, Yin S, Yan X, Chen Y, Zhu C, Li J, Liu X, Wu C, Huang R.
    Virulence; 2024 Dec; 15(1):2404965. PubMed ID: 39317345
    [Abstract] [Full Text] [Related]

  • 2. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study.
    Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS.
    World J Gastroenterol; 2020 Apr 07; 26(13):1525-1539. PubMed ID: 32308352
    [Abstract] [Full Text] [Related]

  • 3. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 07; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 4. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec 07; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A.
    Antiviral Res; 2016 Dec 07; 136():32-36. PubMed ID: 27793564
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 07; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 12. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
    Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J, Chronic Hepatitis B Study Consortium.
    Gut; 2016 Feb 07; 65(2):313-20. PubMed ID: 25586058
    [Abstract] [Full Text] [Related]

  • 13. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A, Jansen L, Zaaijer HL, Klause U, Takkenberg B, Janssen HL, Chu T, Petric R, Reesink HW.
    Antivir Ther; 2014 Feb 07; 19(3):259-67. PubMed ID: 24256626
    [Abstract] [Full Text] [Related]

  • 14. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar 07; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

  • 15. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Mar 07; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 16. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
    Chen Q, Zhang J, Huang J, Quan B, Wu X, Deng S, Han W.
    Med Sci Monit; 2019 Jun 23; 25():4665-4674. PubMed ID: 31230063
    [Abstract] [Full Text] [Related]

  • 19. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
    Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, Zhou Z, Shi X.
    Front Cell Infect Microbiol; 2023 Jun 23; 13():1332232. PubMed ID: 38292859
    [Abstract] [Full Text] [Related]

  • 20. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2023 Jun 23; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.